Protalix BioTherapeutics, Inc.
PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipelā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.75
Price-2.78%
-$0.05
1Y
Price
Market Cap
$140.737m
Small
Price/Earnings 3y Avg5y Avg
21.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+15.6%
EBITDA Margin+13.2%
Net Profit Margin-23.7%
Free Cash Flow Margin+15.6%
EBITDA Margin+13.2%
Net Profit Margin-23.7%
Free Cash Flow MarginRevenue
$61.840m
+15.8%
1y CAGR+11.6%
3y CAGR+14.8%
5y CAGREarnings
$5.394m
+84.0%
1y CAGR+58.3%
3y CAGR+55.2%
5y CAGREPS
$0.07
+75.0%
1y CAGR+49.1%
3y CAGR+49.3%
5y CAGRBook Value
$52.908m
$82.264m
Assets$29.356m
Liabilities$8.177m
DebtDebt to Assets
9.9%
0.9x
Debt to EBITDAFree Cash Flow
-$11.692m
-258.2%
1y CAGR+77.3%
3y CAGR+28.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company